SNDX Quote, Financials, Valuation and Earnings

Moderna has a net margin of -673.01% compared to Syndax Pharmaceuticals's net margin of 0.7%. Syndax Pharmaceuticals's return on equity of -67.33% beat Moderna's return on equity of -17.44%.

Syndax Pharmaceuticals has a consensus price target of $36.46, signalling upside risk potential of 189.38%. On the other hand Moderna has an analysts' consensus of $69.87 which suggests that it could grow by 102.75%. Given that Syndax Pharmaceuticals has higher upside potential than Moderna, analysts believe Syndax Pharmaceuticals is more attractive than Moderna.

Syndax Pharmaceuticals has a beta of 0.891, which suggesting that the stock is 10.888% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

Syndax Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Syndax Pharmaceuticals quarterly revenues are $12.5M, which are smaller than Moderna quarterly revenues of $1.9B. Syndax Pharmaceuticals's net income of -$84.1M is lower than Moderna's net income of $13M. Notably, Syndax Pharmaceuticals's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals is -- versus 2.64x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -673.01% compared to Syndax Pharmaceuticals's net margin of -49.65%. Syndax Pharmaceuticals's return on equity of -67.33% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Syndax Pharmaceuticals has a consensus price target of $36.46, signalling upside risk potential of 189.38%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 423.91%. Given that NovaBay Pharmaceuticals has higher upside potential than Syndax Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Syndax Pharmaceuticals.

Syndax Pharmaceuticals has a beta of 0.891, which suggesting that the stock is 10.888% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Syndax Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Syndax Pharmaceuticals quarterly revenues are $12.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Syndax Pharmaceuticals's net income of -$84.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Syndax Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals is -- versus 0.08x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -673.01% compared to Syndax Pharmaceuticals's net margin of -2357.27%. Syndax Pharmaceuticals's return on equity of -67.33% beat Palatin Technologies's return on equity of --.

Syndax Pharmaceuticals has a consensus price target of $36.46, signalling upside risk potential of 189.38%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1417.86%. Given that Palatin Technologies has higher upside potential than Syndax Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Syndax Pharmaceuticals.

Syndax Pharmaceuticals has a beta of 0.891, which suggesting that the stock is 10.888% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Syndax Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Syndax Pharmaceuticals quarterly revenues are $12.5M, which are larger than Palatin Technologies quarterly revenues of $350K. Syndax Pharmaceuticals's net income of -$84.1M is lower than Palatin Technologies's net income of -$7.8M. Notably, Syndax Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -673.01% compared to Syndax Pharmaceuticals's net margin of 37.71%. Syndax Pharmaceuticals's return on equity of -67.33% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Syndax Pharmaceuticals has a consensus price target of $36.46, signalling upside risk potential of 189.38%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $489.81 which suggests that it could grow by 18.98%. Given that Syndax Pharmaceuticals has higher upside potential than Vertex Pharmaceuticals, analysts believe Syndax Pharmaceuticals is more attractive than Vertex Pharmaceuticals.

Syndax Pharmaceuticals has a beta of 0.891, which suggesting that the stock is 10.888% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

Syndax Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syndax Pharmaceuticals pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Syndax Pharmaceuticals quarterly revenues are $12.5M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Syndax Pharmaceuticals's net income of -$84.1M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Syndax Pharmaceuticals's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syndax Pharmaceuticals is -- versus 10.08x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.